Risk factors
Zymeworks (ZYME) risk factors
Item 1A of every Zymeworks Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
60 risks, 12 new, 20 dropped, 34 reworded since the prior year. Zymeworks is shifting toward an unproven royalty-driven asset aggregation strategy through partnering and potential acquisitions. Regulatory approvals for Ziihera expanded across the U.S., China, and Europe. Loan agreements with Royalty Pharma restrict actions regarding Ziihera and Jazz/BeOne collaborations.
Filed Mar 02, 2026 - FY2024 10-K risk factors
68 risks. Zymeworks relies heavily on partner Jazz for commercializing Ziihera and advancing zanidatamab. The company faces high clinical trial, regulatory, and patent protection risks across its early-stage pipeline.
Filed Mar 05, 2025